External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Haematology SOHO 2024
Roche and Genentech at

SOHO 2024

September 04 - September 07
Houston, Texas
soho.com
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon
01:15 PM
Duration 45mins Houston, Texas
Real-World Comparative Outcomes of First-Line (1L) Venetoclax + Obinutuzumab▼ (VenO) versus Bruton's Tyrosine Kinase Inhibitors (BTKis) Anti-CD20 Therapy Among Patients with Chronic Lymphocytic Leukemia (CLL) in the United States (US)
Li S, Ravelo A, Schuldt R, Shahkarami M, Thompson MC
Haematology - Oncology | Chronic Lymphocytic Leukaemia

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 45mins Houston, Texas
Real-World Healthcare Costs Among Patients with Chronic Lymphocytic Leukemia Receiving First-Line Treatment with Venetoclax + Obinutuzumab▼ versus Bruton's Tyrosine Kinase Inhibitors
Ravelo A, Patel A, To TM, Li SS, Huntington S
Haematology - Oncology | Chronic Lymphocytic Leukaemia

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.